PA
VRTX icon

Prossimo Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Prossimo Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,975
Closed -$879K – 124
2025
Q2 		$879K Sell
1,975
-80
-4% -$36.9K 0.71% 36
2025
Q1 		$996K Buy
2,055
+6
+0.3% +$2.8K 0.75% 37
2024
Q4 		$825K Sell
2,049
-38
-2% -$17.6K 0.6% 47
2024
Q3 		$971K Buy
2,087
+459
+28% +$220K 0.71% 40
2024
Q2 		$763K Buy
1,628
+15
+0.9% +$6.51K 0.69% 43
2024
Q1 		$674K Buy
1,613
+125
+8% +$52.8K 1.3% 18
2023
Q4 		$605K Buy
1,488
+319
+27% +$118K 1.28% 26
2023
Q3 		$407K Buy
1,169
+140
+14% +$49K 0.96% 38
2023
Q2 		$362K Buy
1,029
+5
+0.5% +$1.69K 0.35% 92
2023
Q1 		$323K Buy
+1,024
New +$307K 0.79% 44

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Prossimo Advisors's VRTX Position: Q3 2025 in Review

Prossimo Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,975 shares — an estimated $879K sold.

Prossimo Advisors first reported a position in VRTX in Q1 2023 and held it in 10 quarters. The position peaked at $996K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Prossimo Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prossimo Advisors sold 1,975 Vertex Pharmaceuticals shares in Q3 2025, an estimated $879K.
  • Prossimo Advisors first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Prossimo Advisors's Vertex Pharmaceuticals position peaked at $996K in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Prossimo Advisors's 13F filing for Q3 2025, filed 28 Oct 2025.